Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000796 · ClinicalTrials.gov registry record · NA
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 525
- Enrollment target
NCT00000796: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000796 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 525 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000796, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 525 participants
- Enrollment target
Study Summary
To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the clinical and microbiological responses and overall survival of MDRTB patients who are treated with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list. Per 9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of patients who show failure or relapse are due to the same strain or reinfection with a new strain. Among TB patients, there has been an increase in progressive disease due to the emergence of antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify patients at high risk for MDRTB increases the hazard for both treatment failure and development of resistance to additional therapeutic agents. Efforts to improve survival in patients with MDRTB will depend on improved methods of assessing the risk of acquisition of MDRTB and identifying drug susceptibility patterns in a timely fashion.
Interventions
- DRUG Cycloserine
- DRUG Ethionamide
- DRUG Capreomycin sulfate
- DRUG Aminosalicylic acid
- DRUG Streptomycin sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Est. Completion | 1998-10 |
| Phase | NA |
What the finished NCT00000796 record still lists
NCT00000796 is an interventional study that assigns participants to a tested intervention. The registered 525 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 5 interventions - of which Cycloserine is the first listed.
NCT00000796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000796 about?
NCT00000796 is a clinical study titled "A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.". To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the clinical and microbiological responses and overall survival of MDRTB patients who are treated with levofloxacin-contai...
What is the current status of trial NCT00000796?
This trial is currently completed. It is a NA study. The enrollment target is 525 participants. Estimated completion is 1998-10.
What interventions are being tested in trial NCT00000796?
The interventions under investigation include: Cycloserine (DRUG), Ethionamide (DRUG), Capreomycin sulfate (DRUG), Aminosalicylic acid (DRUG), Streptomycin sulfate (DRUG).
Who is sponsoring clinical trial NCT00000796?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000796's enrollment target sits among peer trials
525 189th of 2000 higher than 1,812 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
- NCT06496646 · 525 participants · NA
Antidepressant Adherence for Depressed Adults in Primary Care